Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b

PHASE2CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

November 27, 2017

Primary Completion Date

August 29, 2018

Study Completion Date

November 21, 2018

Conditions
Chronic Hepatitis C Genotype 1b
Interventions
DRUG

Narlaprevir

100 mg, oval shaped, concave, yellow film-coated, tablets taken as 200 mg per os daily

DRUG

Ritonavir

100 mg, tablets, taken as 100 mg per os daily

DRUG

Daclatasvir

60 mg, tablets, taken as 60 mg per os daily

Trial Locations (4)

Unknown

FBIS CSRI of Epidemiology of Federal Service on Customers, Moscow

SBEI HPE Moscow State Medical and Dental University n.a. A.I. Evdokimov of Ministry of Health of Russia, Moscow

"SBHI of Moscow City Clinical Hospital #24", Moscow

St. Petersburg SBHI Center of Prevention and Fight against AIDS and Infection Diseases, Saint Petersburg

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Almedis

INDUSTRY

lead

R-Pharm

INDUSTRY

NCT03485846 - Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b | Biotech Hunter | Biotech Hunter